The study involves administration of a single or multiple doses of MultiStem, an allogeneic cell therapy product, to patients following radiation therapy and a donor-derived hematopoietic stem cell transplant...Paris-based Sanofi-Aventis Group and its wholly owned subsidiary, BiPar Sciences, of South San Francisco, announced that The New England Journal of Medicine published the final Phase II data for iniparib (BSI-201) demonstrating significant clinical benefit in women with metastatic triple

trial in stroke patients to study a unique stem cell population as a regenerative therapy given two weeks after the stroke...The trial is designed to assess the safety of ALD-401 and its potential efficacy to improve clinical outcomes in patients with ischemic strokes when administered 13 and 19 days after the stroke

The FDA has cleared a stem cell therapy by Advanced Cell Technology Inc., of Santa Monica, Calif., for Phase I/II trials for Stargardt's macular degeneration (SMD...The stem cells are designed to replace retinal pigment epithelium cells, which are lost in SMD, and have been shown to have the desired effect in a mouse model of the disease

The funds will take the vaccine up to late-stage clinical development...trials for cardiac therapies based on the company's mix of stem cells derived from cardiac tissue, which aim to regenerate damaged areas of the heart and improve heart function...Clinical studies are slated to start in early 2011

Clinical Data Inc., of Newton, Mass., reported results of two Phase I studies demonstrating that vilazodone, a dual-acting modulator of serotonin neurotransmission in development for the treatment of major depressive disorder, did not prolong the QT interval and that alteration of gastric pH does not adversely affect its pharmacokinetics...The results were presented in Anaheim, Calif., at the 2010 Midyear Clinical & Exhibition Meeting of the American Society of Health-System Pharmacists...The results

Gentium SpA, of Villa Guardia, Italy, presented clinical results for Defibrotide in patients veno-occlusive disease (VOD) and multi-organ failure (MOF) from several studies...Spectrum Pharmaceuticals Inc., of Irvine, Calif., presented Zevalin (ibritumomab tiuxetan) data as a preparatory or conditioning regimen prior to both allogeneic and autologous stem cell transplantation

It will be the first clinical trial of neural stem cells for spinal cord injury

BioCryst Pharmaceuticals Inc., of Birmingham, Ala., presented data that confirmed clinical activity of its drug forodesine in chronic lymphocytic leukemia...ChemGenex Pharmaceuticals Ltd., of Melbourne, Australia, presented updated clinical data showing that Omapro (omacetaxine mepesuccinate) produced durable hematologic and cytogenetic responses in a significant proportion of chronic phase chronic myeloid leukemia (CML) patients who had failed previous attempts to control their disease with two or

adult stem cells includes a collection, storage and processing service as well as a research and development unit for stem cell therapies, including VSEL technology acquired from the University of Louisville, in 2006...Cancer stem cell company Verastem Inc., of Boston, closed a $16 million Series A financing led by Longwood Founders Fund...Bessemer Venture Partners, Cardinal Partners and MPM Capital joined in the financing, which will be used by the company to advance discovery of stem cell therapies

Stem Cells Inc., of Palo Alto, Calif., applied to Swissmedic, the Swiss drug regulatory agency, to conduct a trial of its human neural stem cell product, HuCNS-SC for spinal cord injury...Stem Cells' stock (NASDAQ:STEM) closed at $1.05, up 3 cents, on Monday

Stem Cell Therapeutics Corp., of Calgary, Alberta, filed a preliminary short form base shelf prospectus with Canadian securities commissions in British Columbia, Alberta, Manitoba, Ontario and Nova Scotia for offerings of common shares, warrants or units providing up to C$15 million (US$14,948,789) in aggregate over the next 25 months...The company plans to use the proceeds to fund ongoing R&D, working capital and general corporate activities, including clinical trials on its drug-based therapies

The firm plans to use the capital raised through the warrant exercises to strengthen its working capital reserves and for the expansion of its stem cell product development, including product development being undertaken at its subsidiaries Embryome Sciences Inc., OncoCyte Corp., OrthoCyte Corp., BioTime Asia Ltd...Common stock to be outstanding after the offering was 50.5 million shares.

Stem Cell Therapeutics Corp., of Calgary, Alberta, said that shareholders and brokers have completed the execution of 12,210,000 warrants with proceeds of C$1,822,000 (US$1,806,267...The funds will be used for ongoing research and development activities, working capital and general purposes including the company's clinical trial program. (See BioWorld Today, May 26, 2010.)

StemCells Inc., of Palo, Calif., started a second clinical trial of HuCNS-SC, purified human neural stem cells, in Batten disease (neuronal ceroid lipofuscinosis), a fatal neurodegenerative disorder in children

and Germany, in which stem cell recipients at risk for developing HCMV viremia and disease are being treated prophylactically after transplantation. (See BioWorld Today, July 22, 2010, May 11, 2010, and April 15, 2010...The company said the next step in the clinical development of IMO-3100 will be a Phase II clinical trial in a selected autoimmune disease indication. (See BioWorld Today, Aug. 4, 2010

plc, of Dublin, Ireland, reported data further supporting the potential clinical use of an investigational assay detecting anti-JC virus antibodies in human plasma or serum, which may provide a means to segment multiple sclerosis patients receiving Tysabri (natalizumab) treatment...Neuralstem Inc., of Rockville, Md., said a safety monitoring board reviewed the first six patients treated in the company's ongoing Phase I trial of spinal cord stem cells for amyotrophic lateral sclerosis and allowed

NOX-A12, aimed at autologous stem cell transplantation in hematological disorders, has been evaluated in models of stem cell mobilization, angiogenesis, inflammation and lung and kidney injury...The first-in-human clinical trial for NOX-A12 was successfully completed in May in healthy individuals following intravenous administration of the drug candidate

Geron Corp., of Menlo Park, Calif., initiated its Phase I trial of GRNOPC1, a human embryonic stem cell-derived oligodendrocyte progenitor cell therapy, for spinal cord injuries...The 24-to-30 patient study will evaluate safety, tolerability, pharmacokinetics and changes in MS clinical status

The clinical trial is the first to evaluate purified neural stem cells as a potential treatment for a myelination disorder